Rigel Pharmaceuticals (RIGL) Net Cash Flow (2010 - 2026)

Rigel Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$16.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 47.51% year-over-year to -$16.2 million; the TTM figure through Mar 2026 stood at -$21.3 million (down 205.47% YoY), while the FY2025 annual figure was -$16.1 million, down 167.23% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$16.2 million, down from -$8.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $15.8 million in Q1 2023, with the low at -$16.2 million in Q1 2026.
• The 5-year median for Net Cash Flow is $2.5 million (2022), against an average of $328117.6.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 560.24% in 2024, then tumbled 257.38% in 2025.
• Rigel Pharmaceuticals' Net Cash Flow stood at -$5.4 million in 2022, then slumped by 133.55% to -$12.6 million in 2023, then jumped by 140.02% to $5.1 million in 2024, then sank by 257.38% to -$8.0 million in 2025, then slumped by 103.28% to -$16.2 million in 2026.
• Business Quant data shows RIGL's Net Cash Flow at -$16.2 million in Q1 2026, -$8.0 million in Q4 2025, and -$4.9 million in Q3 2025.